SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 19 nM for human CB2 receptors, and 134 nM for human CB1 receptors.[1][2] It was discovered during research into the related compound SDB-001 which had been sold illicitly as "2NE1".[3] SDB-006 metabolism has been described in literature.[4]
^Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M (January 2018). "The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs". Drug Testing and Analysis. 10 (7): 1099–1109. doi:10.1002/dta.2362. PMID29350472.
^Diao X, Carlier J, Scheidweiler KB, Huestis MA (July 2017). "In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology. 35 (2): 252–262. doi:10.1007/s11419-016-0350-9. S2CID26558377.